Sangamo BioSciences Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $21.416M Miss $21.43M Estimate; Expects To Have Cash, Cash Equivalents, Marketable Securities, Interest Receivable Of At Least $380M At End Of 2018
Benzinga Newsdesk